Pharmaceutical Business review -

Pharmaceutical Business review is using cookies

Continue Learn More

Close

November 19, 2018

AstraZeneca’s Imfinzi fails to improve OS in Mystic lung cancer trial

AstraZeneca’s Imfinzi (durvalumab) monotherapy and the combination of Imfinzi with remelimumab have failed to improve overall survival (OS) rate in phase III Mystic lung cancer trial.

Image: AstraZeneca’s Imfinzi has failed to improve OS in lung cancer trial. Photo: courtesy of AstraZeneca.

November 15, 2018

Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial

Image: Merck’s anti-PD-1 therapy Keytruda. Photo: courtesy of Merck Sharp & Dohme Corp.

November 14, 2018

FDA grants priority review to Tecentriq combo for triple-negative breast cancer

Image: Roche’s Tecentriq gets FDA priority review for triple-negative breast cancer. Photo: courtesy of F. Hoffmann-La Roche Ltd.

Contracts

October 8, 2018

hVIVO signs new contracts with global biopharmaceutical firm

Image: hVIVO has signed new contracts with global biopharmaceutical firm. Photo: courtesy of rawpixel / Unsplash.

Opiant signs contract with BARDA to accelerate OPTN003 product development

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

Drug Manufacturing

Data science company IXICO extends contract with biopharmaceutical firm

Deals

Deals November 14, 2018

AstraZeneca to sell Synagis US rights to Sobi for $1.5bn

Pharmaceutical Business Review

BioTime signs merger deal with Asterias Biotherapeutics

IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

Popular

Videos

Suppliers

Spotlight

Pharmaceutical Business Review

Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis

Pharmaceutical Business Review

Lynparza maintenance therapy secures FDA priority review for ovarian cancer

Pharmaceutical Business Review

Nestlé Health Science increases stake in Aimmune Therapeutics